- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
8
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
8 companies
Xeris Biopharma Holdings
Market Cap: US$1.6b
A commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
XERS
US$8.60
7D
3.2%
1Y
13.3%
Natera
Market Cap: US$46.9b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$324.84
7D
4.5%
1Y
100.6%
Teva Pharmaceutical Industries
Market Cap: US$43.7b
Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
TEVA
US$36.81
7D
0.8%
1Y
95.8%
AbbVie
Market Cap: US$470.0b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$261.83
7D
4.4%
1Y
25.0%
Sotera Health
Market Cap: US$5.4b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$19.22
7D
1.1%
1Y
20.7%
Tempus AI
Market Cap: US$11.1b
Operates as a healthcare technology company in the United States.
TEM
US$66.65
7D
22.8%
1Y
-13.1%
Merck
Market Cap: US$375.5b
Operates as a healthcare company worldwide.
MRK
US$148.99
7D
9.9%
1Y
73.1%
Ligand Pharmaceuticals
Market Cap: US$5.7b
A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
LGND
US$287.39
7D
-2.4%
1Y
80.7%